

Kala Pharmaceuticals Presents at the Ophthalmology Innovation Summit

WALTHAM, Mass., April 16, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, announced that Charlie McDermott, Interim President and Chief Business Officer of Kala, will participate today in the Ophthalmology Innovation Summit in San Diego, CA. Mr. McDermott will discuss Kala's MPP technology and lead candidate KPI-121, a novel nanoparticle formulation of loteprednol etabonate ("LE"), on the panel entitled, "Spotlight on Drug Delivery," taking place from 2:10 – 2:50 PM Pacific Daylight Time. Additionally, Mr. McDermott will highlight the recently announced positive data for KPI-121, including results from its Phase 3 trial for the treatment of inflammation and pain in patients who had undergone cataract surgery, as well as results from the Phase 2 trial in patients with dry eye syndrome.

The [Ophthalmology Innovation Summit](#) highlights companies developing ground-breaking ophthalmic technologies and connects them with other business leaders and physicians in the field who are driving ophthalmic innovation.

About KPI-121

KPI-121 is a novel nanoparticle formulation of loteprednol etabonate utilizing Kala's proprietary MPP technology to enhance penetration into target tissues of the eye. KPI-121 has been studied in multiple clinical trials, including 1% and 0.25% formulations for the treatment of post-surgical ocular inflammation and pain and a 0.25% formulation for dry eye and meibomian gland disease.

About Kala Pharmaceuticals, Inc.

Kala is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Beyond ophthalmology, Kala's MPP technology has potential applications in women's reproductive health, respiratory and gastrointestinal diseases, and other indications.

Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, and is backed by leading life sciences investors including Crown Venture Fund, Lux Capital,

Polaris Partners, Third Rock Ventures and Ysios Capital. For more information, please visit Kala's website at www.kalarx.com.

Contact:

Kari Watson

(781) 235-3060

kwatson@macbiocom.com

or Hunter Marshall

(650) 342-1000

hmarshall@macbiocom.com

MacDougall Biomedical Communications